Tirzepatide vs Semaglutide: The SURMOUNT-5 Head-to-Head and What It Settled

Tirzepatide is, by most objective measures, the most effective anti-obesity medication ever brought to market. For years that claim rested on cross-trial comparisons against semaglutide — same direction, same magnitude, never head-to-head. In May 2025 the actual head-to-head trial finally read out, and it confirmed what the indirect data had been pointing to: SURMOUNT-5 (NEJM, May 11 2025) showed tirzepatide produced -22.8 kg average weight loss versus semaglutide's -15.0 kg over 72 weeks in adults with obesity.

This article walks through the full picture: SURMOUNT-5 in detail, the four-trial SURMOUNT program that came before it, the GIP receptor debate that's still unresolved, and the Mounjaro vs Zepbound brand-equivalence question that confuses a lot of people.

Tirzepatide hits both GLP-1 and GIP receptors, which makes it the first approved dual incretin agonist. SURMOUNT-1 produced 22.5% average weight loss at 72 weeks in people with obesity. SURMOUNT-5 then put it head-to-head against semaglutide and confirmed the gap directly: -22.8 kg vs -15.0 kg over 72 weeks. Four SURMOUNT trials total now cover obesity, type 2 diabetes, and weight maintenance. The GIP receptor question — should you activate it or block it? — is still one of the most interesting open arguments in metabolic pharmacology. The molecule is sold as Mounjaro for diabetes and Zepbound for obesity. Same compound, different labels, different insurance conversations.

The dual agonist mechanism

Tirzepatide is a 39-amino acid peptide based on the GIP sequence but engineered to also activate the GLP-1 receptor. The binding profile is intentionally asymmetric: it activates the GIP receptor with roughly equal potency to native GIP, but activates the GLP-1 receptor at about one-fifth the potency of native GLP-1. This isn't a limitation — it's by design.

The GLP-1 side

The GLP-1 receptor activation does what GLP-1 agonists do: suppresses appetite through hypothalamic signaling, slows gastric emptying, enhances glucose-dependent insulin secretion, and suppresses inappropriate glucagon release. This is the well-understood half of the molecule — decades of research on semaglutide, liraglutide, and other GLP-1 agonists have mapped this pathway thoroughly.

The GIP side — and the controversy

This is where things get genuinely interesting. GIP (glucose-dependent insulinotropic polypeptide) was historically considered an "obesogenic" hormone — some older research suggested that GIP signaling promoted fat storage. This led to a competing hypothesis: maybe you should block GIP, not activate it.

The agonism camp, supported by tirzepatide's clinical data, argues that GIP receptor activation improves fat metabolism, enhances insulin sensitivity through pathways independent of GLP-1, and may contribute to lean mass preservation during weight loss. The evidence is straightforward: tirzepatide, a potent GIP agonist, produces more weight loss than semaglutide, which has no GIP activity. If GIP agonism promoted fat storage, tirzepatide should perform worse, not better.

The antagonism camp points to preclinical data showing that GIP receptor knockout mice are protected from diet-induced obesity, and that GIP antagonist antibodies (like AMG 133, now maridebart cafraglutide) also produce significant weight loss when combined with GLP-1 agonism. Their argument: maybe tirzepatide works well despite GIP agonism, not because of it.

The resolution may be more nuanced. Some researchers propose that GIP receptor activation in the brain may function differently than in peripheral tissues. Central GIP signaling may suppress appetite and improve energy homeostasis, while peripheral GIP signaling has tissue-specific effects that depend on metabolic context. The same receptor, different outcomes depending on where it's activated.

This debate isn't just academic — it has implications for next-generation drug design. The honest answer is that we don't know yet, and anyone who tells you definitively is getting ahead of the data.

The SURMOUNT trials

Eli Lilly ran four major Phase 3 trials under the SURMOUNT banner, each designed to answer a different clinical question.

SURMOUNT-1: the flagship trial

Published in the New England Journal of Medicine, 2022. This was the trial that put tirzepatide on the map for obesity.

The trial enrolled 2,539 adults with BMI of 30 or higher (or 27+ with at least one comorbidity) without type 2 diabetes, and ran for 72 weeks. At the 15mg dose, average weight loss was 22.5% of baseline body weight. 63% of participants achieved at least 20% weight loss, and 36% achieved at least 25%. There were also significant improvements in waist circumference, blood pressure, triglycerides, and fasting insulin.

To put 22.5% in context: the FDA historically considered 5% weight loss from baseline to be clinically meaningful. Tirzepatide delivered four and a half times that threshold.

SURMOUNT-2: obesity with type 2 diabetes

People with type 2 diabetes typically lose less weight on anti-obesity medications — the metabolic environment is different, and diabetes medications can promote weight gain. SURMOUNT-2 tested whether tirzepatide could overcome this.

Average weight loss was approximately 14.7% at the 15mg dose over 72 weeks, along with dramatic improvements in HbA1c. While less than SURMOUNT-1 — expected given the population — it was still far superior to any existing diabetes medication and most anti-obesity medications.

SURMOUNT-3: after lifestyle intervention

This trial was clever in its design. Participants first completed a 12-week intensive lifestyle intervention (structured diet and exercise), losing an average of 6.9% body weight. Then they were randomized to tirzepatide or placebo.

Participants on tirzepatide lost an additional 18.4% of body weight on top of the lifestyle-induced loss, for a total average from original baseline of approximately 26.6%. The placebo group regained most of what they'd lost during the lifestyle phase. This demonstrated that tirzepatide and lifestyle intervention have additive effects — they're not redundant.

SURMOUNT-4: the maintenance question

Perhaps the most important trial for long-term clinical planning. All participants received open-label tirzepatide for 36 weeks, losing substantial weight. Then they were randomized to continue tirzepatide or switch to placebo.

Those who continued maintained their weight loss and continued to lose additional weight. Those switched to placebo regained approximately half the weight they'd lost within the following 52 weeks. This confirms what the field suspected: tirzepatide, like other GLP-1-based therapies, requires ongoing treatment to maintain benefit. The weight regain on discontinuation reflects the biology of obesity, not a flaw in the drug.

Cardiovascular outcomes

For any metabolic therapy, the cardiovascular question is paramount — weight loss drugs that increase heart attacks or strokes are worse than useless. Tirzepatide's cardiovascular outcomes data comes from the SURPASS-CVOT trial.

The trial demonstrated that tirzepatide was non-inferior to placebo for major adverse cardiovascular events (MACE) in patients with type 2 diabetes — meaning it doesn't increase cardiovascular risk. Additional analyses suggested potential benefit, including reductions in blood pressure, atherogenic lipids, and inflammatory markers, though the trial wasn't powered to demonstrate superiority on hard cardiovascular endpoints.

This matters because semaglutide's SELECT trial demonstrated cardiovascular superiority — actual reduction in heart attacks and strokes. Whether tirzepatide can match that in a dedicated outcomes trial is an open question. The metabolic improvements it produces are at least as comprehensive as semaglutide's, so the biological plausibility is there.

SURMOUNT-5: the head-to-head finally read out

For years the tirzepatide-vs-semaglutide question had to be answered with cross-trial comparisons (SURMOUNT-1 vs STEP 1) and a head-to-head in type 2 diabetes (SURPASS-2). Both pointed the same direction. But the obesity-specific head-to-head trial people kept asking for didn't exist — until May 11, 2025, when SURMOUNT-5 was published in the New England Journal of Medicine and presented at the European Congress on Obesity.

Here's how the trial was set up. 751 adults with obesity (BMI ≥30, or ≥27 with weight-related comorbidities), no type 2 diabetes, randomized 1:1 to either tirzepatide or semaglutide — same once-weekly injection cadence for both. Each compound was titrated up to its maximum tolerated approved obesity dose: tirzepatide 10 or 15 mg, semaglutide 1.7 or 2.4 mg, alongside behavior support. Seventy-two weeks total. It was open-label, which isn't ideal — but the two injection devices look different enough that you can't really blind it, so that's an unavoidable limitation rather than a design choice.

The results were decisive. Average body weight loss came in at -22.8 kg on tirzepatide and -15.0 kg on semaglutide — about an 8 kg gap, in tirzepatide's favor. Roughly a third of the tirzepatide group lost at least 25% of their body weight. Roughly an eighth of the semaglutide group did. Waist circumference dropped further on tirzepatide too.

What's almost more interesting is the tolerability side, which went the same direction. People dropped out from GI side effects more often on semaglutide (5.6%) than on tirzepatide (2.7%) — meaning tirzepatide produced more weight loss and fewer people quit because of nausea. There's a working hypothesis for why: GIP receptor activation may have an anti-emetic effect that takes some of the edge off the nausea GLP-1 is driving. If that's right, the dual mechanism is buying you more weight loss per unit of side effect, not less.

The data confirmed what the cross-trial comparisons had been pointing to all along. SURMOUNT-1 vs STEP 1 indirectly suggested tirzepatide 15mg at 22.5% weight loss versus semaglutide 2.4mg at 16.9%. SURMOUNT-5 made it direct: tirzepatide -22.8 kg vs semaglutide -15.0 kg, head-to-head, same trial, same population, same titration approach. Whether the superiority reflects the GIP receptor contribution specifically, differences in GLP-1 receptor engagement kinetics, or some combination is still debated — but the magnitude of the effect is no longer in question.

The lean mass hypothesis

One of the more intriguing aspects of tirzepatide research is the body composition data. In SURMOUNT-1, participants losing 22.5% of body weight maintained a favorable lean-to-fat mass ratio — approximately 75-80% of weight lost was fat mass.

Some researchers attribute this to GIP receptor activation. The hypothesis is that GIP signaling in muscle tissue may promote protein synthesis or inhibit protein breakdown, effectively sparing lean mass during rapid weight loss. If true, this would be a significant advantage of dual agonism over pure GLP-1 therapy, because muscle loss during aggressive weight reduction is a genuine clinical concern — especially in older adults, where sarcopenia is already a problem.

The evidence is suggestive but not conclusive. Preclinical models show GIP receptors on muscle tissue and demonstrate effects on muscle protein turnover. The clinical body composition data is consistent with the hypothesis. But a definitive causal link between tirzepatide's GIP activation and lean mass preservation hasn't been established in humans.

Mounjaro vs. Zepbound: same molecule, different label

A source of persistent confusion. Mounjaro and Zepbound are the same molecule — tirzepatide — manufactured by the same company (Eli Lilly) at the same facilities. The difference is purely regulatory.

Mounjaro was approved first with an indication for type 2 diabetes, receiving FDA approval in 2022 based on the SURPASS trial program. Zepbound was approved subsequently for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity, receiving FDA approval in 2023 based on the SURMOUNT program.

The dosing is identical. The injection device is identical. The molecule is identical. The distinction exists because the FDA requires separate approvals for different indications, and insurance coverage often differs between the two labels. This has created access challenges — the same patient taking the same drug might have coverage under one brand name but not the other, depending on their diagnosis.

The Dose-Response Story

Tirzepatide uses a gradual dose escalation that's become standard in the GLP-1 class — each step up increases efficacy but also increases the likelihood of gastrointestinal side effects. The specific titration schedule is set by the FDA label and managed by the prescribing physician, not something to design independently.

Significant weight loss occurs even at the lower doses. SURMOUNT-1 showed 15% average weight loss at the 5mg dose and 19.5% at 10mg. Not every patient needs to reach 15mg to achieve meaningful results.

The side effect conversation

The side effect profiles of tirzepatide and semaglutide are broadly similar — both are incretin-based therapies that share GLP-1 receptor activation — but there are nuances worth understanding.

In the SURMOUNT trials, the most common adverse events were gastrointestinal. Nausea affected roughly 25-30% of participants at higher doses, diarrhea 15-20%, constipation 10-15%, and vomiting 5-12%. These rates are comparable to semaglutide's STEP trials, though some analyses suggest tirzepatide may have a slightly lower incidence of nausea at equivalent weight-loss efficacy.

Why might that be? One hypothesis relates to the GIP component. GIP receptor activation may exert an anti-emetic effect that partially counteracts the nausea driven by GLP-1 receptor activation. Preclinical data shows GIP receptor signaling in brain regions that regulate nausea and vomiting. If true, tirzepatide's dual mechanism gives it a tolerability advantage — you get more weight loss per unit of nausea, so to speak.

The more serious adverse events — pancreatitis, gallbladder disease, thyroid effects — occur at low rates in both programs. The FDA label for both carries a boxed warning about thyroid C-cell tumors based on rodent data, though no causal link has been established in humans. Gallbladder-related events occur in approximately 1-2% of participants, likely related to rapid weight loss rather than the drugs specifically.

Injection site reactions are generally mild — some patients report redness or itching that resolves on its own and doesn't require discontinuation.

The compounding landscape

The compounding situation is relevant and evolving. During the FDA-recognized shortage of tirzepatide, compounding pharmacies were able to produce it under the 503B exemption, which significantly expanded access for patients who couldn't obtain or afford the branded versions.

The compounding landscape remains dynamic and subject to regulatory developments. The key considerations are purity, potency testing, and the regulatory framework under which a compounding pharmacy operates. This is an area where the regulatory environment is actively evolving, and the details matter for anyone involved in prescribing or research.

Cost and access

I won't quote specific prices because they change frequently, but the access situation for GLP-1 agonists is one of the most significant challenges in metabolic medicine today. The branded products carry premium pricing, insurance coverage is inconsistent (many plans exclude "weight loss drugs" despite the clinical evidence), and demand exceeds supply.

This creates a situation where a transformative class of medications is available primarily to those who can afford out-of-pocket costs or who happen to have favorable insurance coverage. It's a systemic issue that the field is actively working to address through expanded insurance coverage mandates, manufacturer assistance programs, and the compounding pharmacy ecosystem.

Frequently asked questions

Is tirzepatide better than semaglutide?

For weight loss specifically, yes — confirmed by SURMOUNT-5 (NEJM, May 2025), the first direct head-to-head trial in obesity. Tirzepatide produced -22.8 kg vs semaglutide's -15.0 kg over 72 weeks (Δ -7.9 kg), with roughly a third of the tirzepatide group reaching ≥25% weight loss versus an eighth of the semaglutide group, and lower rates of treatment discontinuation due to GI side effects. Whether "better" extends to cardiovascular outcomes is a separate question — semaglutide has SELECT (a 20% relative risk reduction in major adverse cardiovascular events demonstrated in the NEJM 2023 trial), while tirzepatide's SURPASS-CVOT showed non-inferiority but is not yet powered to demonstrate superiority on hard cardiovascular endpoints.

What happens when you stop taking it?

SURMOUNT-4 showed that participants who discontinued tirzepatide regained approximately half the weight they'd lost within the following year. This is consistent with semaglutide discontinuation data and reflects the biology of obesity — a chronic condition that, for many people, requires ongoing treatment to maintain remission.

What are the most common side effects?

Gastrointestinal effects dominate: nausea (20-30%), diarrhea (15-20%), constipation (10-15%), and vomiting (5-10%). These are most frequent during dose escalation and typically resolve within the first few weeks of each dose level. The gradual titration protocol is designed specifically to minimize them.

How does tirzepatide affect blood sugar?

Tirzepatide was first approved for type 2 diabetes (as Mounjaro) because its metabolic effects are comprehensive. In the SURPASS trials, it produced HbA1c reductions of 2.0-2.3%, making it one of the most effective glucose-lowering agents available. Even in people without diabetes, it significantly improves fasting glucose and insulin sensitivity.

Can tirzepatide be combined with other therapies?

Research on combination approaches is ongoing. The trial programs studied tirzepatide as monotherapy or alongside metformin for diabetes. Combining it with other GLP-1 agonists would be redundant, but combining it with lifestyle intervention (as in SURMOUNT-3) produces additive benefits. Any combination approach should be guided by the evolving clinical evidence.

What's the difference between Mounjaro and Zepbound?

Nothing pharmacologically. Same molecule, same manufacturer, same doses, same injection device. The difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. Insurance coverage and pricing may differ between the two labels depending on diagnosis and plan.